Valuation: Replimune Group, Inc.

Market Cap 1.88B 1.71B 1.58B 1.43B 2.69B 175B 2.8B 19.13B 7.56B 94.72B 7.05B 6.9B 299B P/E 2027 *
-8.59x
P/E 2028 * -17.2x
Enterprise Value 1.65B 1.5B 1.39B 1.26B 2.36B 154B 2.46B 16.8B 6.64B 83.21B 6.19B 6.06B 263B EV / Sales 2027 *
46.8x
EV / Sales 2028 * 7.18x
Free-Float
97.31%
Yield 2027 *
-
Yield 2028 * -
1 day+0.61%
1 week-9.04%
Current month+12.49%
1 month+82.41%
3 months+27.15%
6 months+295.41%
Current year+103.81%
1 week 19.33
Extreme 19.33
22.17
1 month 11
Extreme 10.995
23.54
Current year 1.5
Extreme 1.5
23.54
1 year 1.5
Extreme 1.5
23.54
3 years 1.5
Extreme 1.5
23.54
5 years 1.5
Extreme 1.5
35.06
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/26 A Exercice

Director

107,838 0.1145%
8/20/26 A Don

Founder

-50,000 0.0641%
8/17/26 A Sell

Chief Financial Officer

-9,256 0.0119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%-9.04%+126.66%+90.48% 1.87B
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -0.80%-4.44%+43.41%+160.99% 40B
Weighted average by Cap. -0.84%-3.67%+34.65%+143.73%

Financials

2027 *2028 *
Net sales 35.26M 32.16M 29.73M 26.83M 50.54M 3.3B 52.53M 359M 142M 1.78B 132M 130M 5.62B 209M 190M 176M 159M 299M 19.51B 311M 2.13B 841M 10.53B 783M 767M 33.26B
Net income -233M -213M -197M -178M -335M -21.82B -348M -2.38B -940M -11.78B -876M -858M -37.19B -112M -102M -94.46M -85.25M -161M -10.47B -167M -1.14B -451M -5.65B -420M -411M -17.84B
Net Debt -228M -208M -192M -174M -327M -21.33B -340M -2.32B -919M -11.51B -856M -838M -36.35B -378M -345M -319M -288M -542M -35.34B -563M -3.85B -1.52B -19.07B -1.42B -1.39B -60.23B
Projected Income Statement - Annual - Replimune Group, Inc.
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
18/11/26 $19.81 +0.61% 2,130,080
17/11/26 $19.69 -8.03% 2,434,491
16/11/26 $21.41 -2.19% 2,033,279
13/11/26 $21.89 -0.41% 2,020,798
12/11/26 $21.98 +0.92% 2,892,202
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Replimune Group, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
19.81USD
Average target price
25.50USD
Spread / Average Target
+28.72%
  1. Stock Market
  2. Stocks
  3. REPL Stock